Notably, kidney cancer patients frequently exhibit anemia, with up to 35% of cases demonstrating decreased levels of hemoglobin (HGB), hematocrit (HCT), MCV, and MCH due to the weak activity of erythropoietin (EPO) and abnormal iron metabolism (18, 19). This evidence concerns the gene EPO and anemia (phenotype).